
| Disease Domain | Count | 
|---|---|
| Neoplasms | 10 | 
| Nervous System Diseases | 3 | 
| Immune System Diseases | 1 | 
| Endocrinology and Metabolic Disease | 1 | 
| Top 5 Drug Type | Count | 
|---|---|
| Small molecule drug | 11 | 
| Synthetic peptide | 4 | 
| Diagnostic radiopharmaceuticals | 2 | 
| Contrast agent | 1 | 
| Radiolabeled antibody | 1 | 
| Target | 
| Mechanism PDL1 inhibitors | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target- | 
| Mechanism- | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target | 
| Mechanism GHSR agonists [+1]  | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Start Date24 Mar 2025 | 
| Sponsor / Collaborator | 
| Start Date16 Jan 2025 | 
| Sponsor / Collaborator | 
| Start Date05 Aug 2024 | 
| Sponsor / Collaborator | 

| Drug(Targets) | Indications | Global Highest Phase | 
|---|---|---|
| KP-A038(  RANK ) | Osteoporosis More | Preclinical | 
| 3-DSC(  HMGB1 x factor Xa x thrombin ) | Inflammation More | Preclinical | 
| 64Cu-PCB-TE2A-Tz(  HNRNPA2B1 ) | Triple Negative Breast Cancer More | Preclinical | 
| Piperine(  MAO-B x PXR ) | Glioblastoma More | Preclinical | 
| PD-L1Pep-1-K(  PDL1 ) | Neoplasms More | Preclinical | 





